

Diagnosis of HIV Infection in Infants and Children

Updated: December 19, 2024

Reviewed: December 19, 2024

Panel's Recommendations

- Virologic assays (HIV RNA or HIV DNA nucleic acid tests [NATs]) that directly detect HIV must be used to diagnose HIV in infants and children aged <18 months with perinatal HIV exposure; HIV antibody and HIV antigen/antibody tests should not be used **(AII)**.
 - Plasma HIV RNA or cell-associated HIV DNA NATs are generally equally recommended **(AII)**.
 - An assay that detects HIV non-B subtype viruses or Group O infections (e.g., an HIV RNA NAT or a total DNA/RNA test) is recommended for use in infants and children perinatally exposed to known or suspected non-B subtype virus or Group O infections **(AII)**.
 - Virologic diagnostic testing **using an HIV NAT** (see [Table 13](#) below) is recommended for all infants with perinatal HIV exposure at the following ages:
 - Birth **(AII)**
 - The test at birth generally should be performed in all infants with perinatal HIV exposure but is not necessary for infants at low risk of HIV acquisition (HIV RNA levels <50 copies/mL from 20 weeks of gestation through delivery) or put infants at low risk of HIV acquisition). Birth testing should be performed in infants at low risk of HIV acquisition if there are plans to breastfeed or there are concerns about loss to follow-up **(BIII)**.
 - 14 to 21 days **(AII)**
 - 1 to 2 months **(AII)**
 - 4 to 6 months **(AII)**
 - For infants **who receive presumptive HIV therapy**, additional virologic diagnostic testing is recommended 2 to 6 weeks after **antiretroviral** (ARV) drugs are discontinued **(BII)**.
 - A positive virologic test should be confirmed as soon as possible by a repeat virologic test **(AII)**.
 - Definitive exclusion of HIV infection in non-breastfed infants is based on two or more negative virologic tests **(and no positive virologic tests)**, with one negative test obtained at age ≥ 1 month **(and at least 2–6 weeks after discontinuation of infant ARVs)** and one at age ≥ 4 months, or two negative HIV antibody tests from separate specimens that were obtained at age ≥ 6 months **(AII)**.
 - Additional HIV testing (e.g., HIV NAT, HIV antibody, HIV antigen/antibody) is not needed routinely for non-breastfed infants who meet the criteria for definitive exclusion of HIV and who have had no known or suspected HIV exposure after birth **(AII)**.
 - For infants with perinatal HIV exposure who are being breastfed, virologic diagnostic testing is recommended at birth, 14 to 21 days, 1 to 2 months, and 4 to 6 months of age **(AII)**. An additional virologic test should be performed if the gap between the **tests at ages** 1 to 2 months and 4 to 6 months is greater than 3 months. See [Preventing HIV Transmission During Infant Feeding](#).
 - Virologic diagnostic testing should be performed **at least** every 3 months during breastfeeding **(BII)**;
 - After cessation of breastfeeding, irrespective of when breastfeeding ends, virologic diagnostic testing should be performed at 4 to 6 weeks and **4** to 6 months after cessation **(BII)**.
- Infants with potential HIV exposure after birth (e.g., **diagnosis of HIV during breastfeeding**, pre-masticated feeding, sexual abuse, contaminated blood products, percutaneous exposure) require additional testing using **HIV antigen/antibody and/or HIV NAT assays**, **based on age at time of exposure** and the maternal HIV status at delivery **(AII)**.

- Age-appropriate HIV testing is also recommended for infants and children with signs and/or symptoms of HIV, even in the absence of documented or suspected HIV exposure (AII).
- For children aged ≥ 18 months, HIV antibody (or HIV antigen/antibody) tests are recommended for diagnostic testing (AII).
 - When early (acute or recent) HIV infection is suspected, additional testing with an HIV NAT may be necessary to diagnose HIV infection (AII).

Note: The [National Perinatal HIV Hotline](#) provides consultations on issues related to the management of perinatal HIV infection, including diagnostic testing (1-888-448-8765; 24 hours a day, 7 days a week).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials in children[†] with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children[†] from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children[†] with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children[†] from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion

[†] Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents

Diagnosis of HIV in Infants and Children

HIV can be diagnosed definitively by virologic testing in most non-breastfed infants with perinatal HIV exposure by age 1 to 2 months and in all by age 4 to 6 months. Antibody tests, including antigen/antibody combination immunoassays, do not establish the presence of HIV in infants because HIV antibodies that have been transferred transplacentally **may be detected (i.e., false positive)**; therefore, a virologic test must be used.^{1,2} Positive virologic tests (i.e., nucleic acid tests [NATs]—a class of tests that includes HIV RNA and HIV DNA polymerase chain reaction [PCR] assays and related RNA qualitative or quantitative assays) indicate likely HIV infection. Plasma HIV RNA and HIV DNA NATs are generally equally recommended. However, both tests can be affected by antiretroviral therapy (ART) through transplacental transfer of antiretroviral (ARV) drugs to the fetus during pregnancy or by ARV drugs administered to the infant as prophylaxis or presumptive HIV therapy. In general, qualitative HIV proviral DNA PCR assays from whole blood detecting cell-associated virus are less affected by ARVs.

A positive HIV test result should be confirmed as soon as possible by repeat virologic testing, because false-positive results can occur with both RNA and DNA assays.³ A 2019 systematic review provides additional information on the **global and regional molecular epidemiology** of Group M subtype infections and **recombinants among subtypes**.⁴ Newer HIV RNA PCR assays are usually **“dual-target” assays, which target two separate highly conserved regions on the HIV genome. Dual-target HIV** assays are better than older RNA assays at detecting non-subtype B HIV infection and Group O strains⁵⁻¹⁰ (See [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)).

Antigen/antibody combination immunoassays that detect HIV-1/2 antibodies and HIV-1 p24 antigen **are not recommended** for diagnosis of HIV infection in infants **with known perinatal HIV exposure**. In the first months of life, the antigen component of antigen/antibody tests is less sensitive than an HIV NAT, and antibody tests should not be used for HIV diagnosis in infants and children aged < 18 months.¹¹⁻¹³ Children with perinatal HIV exposure who are aged ≥ 18 months occasionally have residual HIV antibodies from the antepartum period; definitive confirmation of HIV infection in children in this age group who remain HIV antibody-positive should be based on a NAT (see Special

Situations below). Diagnosis in children aged ≥ 18 months relies primarily on HIV antibody and antigen/antibody tests (see Diagnostic Testing in Children with Postnatal HIV Exposure below).¹

An infant who has a positive HIV antibody test but the maternal HIV status is unknown (see [Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure](#)) should be assumed to have been exposed to HIV. The infant should undergo HIV diagnostic testing, as described in Timing of Diagnostic Testing in Infants with Perinatal HIV Exposure below,³ and receive presumptive HIV therapy as soon as possible (see [Antiretroviral Management of Infants with In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)).

Timing of Diagnostic Testing in Infants With Perinatal HIV Exposure

Confirmation of HIV infection is based on the results of positive virologic tests from two separate blood samples in infants and children < 18 months. [Table 13](#) below summarizes the timing of recommended virologic diagnostic testing for infants based on HIV transmission risk. Infants at high risk of perinatal HIV transmission may require additional virologic testing, given the increased risk of infection and concern that ARV prophylaxis, particularly combination ARV prophylaxis or presumptive HIV therapy, may reduce the sensitivity of diagnostic testing. The risk of transmission is determined based on whether ART is being taken and viral suppression is achieved and sustained during pregnancy and postpartum.

HIV infection can be **presumptively excluded** in non-breastfed infants with two or more negative virologic tests (one at age ≥ 2 weeks and one at age ≥ 4 weeks), one negative virologic test at age ≥ 8 weeks at least 2 weeks after discontinuing multidrug ARV prophylaxis/presumptive therapy, or one negative HIV antibody test at age ≥ 6 months.^{1,3}

Definitive exclusion of HIV infection in non-breastfed infants is based on two or more negative virologic tests, with one negative test obtained at age ≥ 1 month (and at least 2–6 weeks after discontinuation of [infant ARVs](#)) and one at age ≥ 4 months, or two negative HIV antibody tests from separate specimens that were obtained at age ≥ 6 months. For both presumptive and definitive exclusion of HIV infection, a child must have no other laboratory evidence (i.e., no positive virologic test results or low CD4 T lymphocyte cell count/percentage) or clinical evidence of HIV infection and must not be breastfeeding. No additional HIV testing of any kind (e.g., NAT, antibody, antigen/antibody) is needed routinely for non-breastfed infants who meet the criteria for definitive exclusion of HIV and who have had no known or suspected HIV exposure after birth.

Pneumocystis jirovecii pneumonia (PCP) prophylaxis is recommended for infants with **indeterminate** HIV infection status starting at age 4 to 6 weeks until they are determined to be definitively or presumptively without HIV infection.¹⁴ Thus, PCP prophylaxis can be avoided or discontinued if HIV infection is presumptively excluded (see [Initial Postnatal Management of the Neonate Exposed to HIV](#) and [Pneumocystis jirovecii Pneumonia](#) in the [Pediatric Opportunistic Infection Guidelines](#)).

Virologic Testing at Birth

Virologic testing at birth [provides insights about the timing of HIV transmission and supports early HIV diagnosis for rapid initiation of ART when indicated](#) (see [When to Initiate Antiretroviral Treatment in Children With HIV Infection](#) in the [Pediatric Antiretroviral Guidelines](#)). Infants who have a positive virologic test result at or before age 48 hours are considered to have early (*in utero*)

infection, whereas non-breastfed infants who have a negative virologic test result during the first week of life and subsequently have positive test results are considered to have late (intrapartum) infection.¹⁵⁻¹⁷

In addition to early HIV diagnosis, results of birth testing are used in clinical decisions about infant ARV management. Negative HIV virologic testing at birth would rule out *in utero* infection and allow de-escalation of a three-drug presumptive HIV therapy regimen for some infants. See [Table 11](#) and associated content in [Antiretroviral Management of Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV](#).

Virologic testing at birth should generally be performed for all infants with perinatal HIV exposure but is not necessary for infants who are at low risk of infection (HIV RNA levels <50 copies/mL from 20 weeks gestation through delivery put infants at low risk of HIV acquisition) unless there are plans to breastfeed. When breastfeeding is planned for an infant at low risk of HIV acquisition, a birth test provides baseline information, should the infant subsequently have a positive test. Virologic testing at birth should also be considered whenever there are concerns that the newborn may be lost to follow-up without testing.

Specimens for HIV testing at birth should be obtained before or immediately after initiating an ARV drug regimen; however, presumptive HIV therapy or ARV prophylaxis should not be delayed.

Blood samples from the umbilical cord should not be used for diagnostic evaluation because of the potential for contamination with maternal blood.

Virologic Testing at Age 14 to 21 Days

Some children with perinatal HIV exposure can have a positive NAT between 14 and 21 days of age.³ Early identification of infection permits transition from presumptive HIV therapy to treatment doses of ART (see [When to Initiate Antiretroviral Treatment in Children With HIV Infection](#) in the [Pediatric Antiretroviral Guidelines](#)).

Virologic Testing at Age 1 to 3 Months

Testing performed at age 1 to 3 months is intended to maximize the likelihood of detecting HIV infection in infants with perinatal HIV exposure. In the HIV Prevention Trials Network 040 study, 93 of 140 infants with HIV (66.4%) were identified at birth. Infants who received negative test results in the first 7 days of life received an HIV diagnosis when the next diagnostic test was performed at 3 months of age.¹⁸ For infants at high risk of perinatal HIV transmission, the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV and the Panel on Treatment of HIV During Pregnancy and Interventions to Reduce Perinatal Transmission suggest performing an additional virologic test 2 to 6 weeks after ARV drugs are discontinued (i.e., at age 8–12 weeks when the infant receives 6 weeks of prophylaxis), given the increased risk of infection and concern that ARV prophylaxis, particularly combination ARV prophylaxis or presumptive HIV therapy, may reduce the sensitivity of diagnostic testing.^{18, 19} In these situations, many experts recommend one test at age 4 to 6 weeks to allow prompt diagnosis of HIV in infants with an additional test at 8 to 12 weeks of life (i.e., 2–6 weeks after cessation of prophylaxis or presumptive HIV therapy) to capture additional cases (see [Table 13](#) below). For infants at low risk of HIV transmission, a single test obtained at 1 to 2 months of age may be timed to occur 2 to 4 weeks after cessation of ARV prophylaxis.

Virologic Testing at Age 4 to 6 Months

Infants with HIV exposure who have had negative virologic assays at age 14 to 21 days and at age 1 to 2 months, who have had no positive virologic tests, who have no clinical evidence of HIV infection, and who are not breastfed should be retested at age 4 to 6 months for definitive exclusion of HIV infection.

Antibody Testing at Age 6 Months and Older

Two or more negative results of HIV antibody tests that were performed in non-breastfed infants at age ≥ 6 months also can be used to exclude HIV infection definitively in children with no clinical or virologic laboratory-documented evidence of HIV infection.^{20, 21}

Antibody Testing at Age ≥ 18 Months to Document Seroreversion

In general, no additional HIV testing of any kind (e.g., NAT, antibody, antigen/antibody) is needed routinely for non-breastfed infants who meet the criteria for definitive exclusion of HIV and who have had no known or suspected HIV exposure after birth.

Virologic Testing for Infants With Perinatal HIV Exposure Who Are Being Breastfed

Some may choose to breastfeed with HIV (see [Preventing HIV Transmission During Infant Feeding](#)). A descriptive study of 72 people with HIV who breastfed their infants in North America reported high variability in policies, infant ARV prophylaxis, and infant and parental testing practices among institutions and noted the need to identify best care practices.²² [Table 13](#) summarizes the recommended diagnostic testing schedule for infants who are being breastfed. Infants with perinatal HIV exposure who are being breastfed should have virologic diagnostic testing at the standard time points: 14 to 21 days, 1 to 2 months, and 4 to 6 months (see [Table 13](#) below). In addition, a virologic test at birth is recommended to provide baseline information should the infant subsequently have a positive test. In some cases, an additional virologic test should be performed between the 1-to-2-month and 4-to-6-month time points if the gap between tests is greater than 3 months. Infants continuing to be breastfed beyond 6 months of age should have virologic diagnostic testing at least every 3 months during breastfeeding. At cessation of breastfeeding, virologic diagnostic testing should be performed at 4 to 6 weeks and 4 to 6 months after breastfeeding has ended, regardless of the age of the child when breastfeeding is discontinued. If the infant is receiving extended ARV prophylaxis during breastfeeding, an additional test should be done at least 2 weeks after cessation of ARV prophylaxis. If an infant's virologic test result is positive, a repeat test should be performed as soon as possible and ART should be initiated.

No data exist to inform the appropriate frequency of maternal viral load testing during breastfeeding. One approach is to monitor plasma viral load every 1 to 2 months during breastfeeding. Additional infant virologic testing using an HIV NAT is indicated if the maternal viral load becomes detectable during breastfeeding (for infant ARV prophylaxis considerations, see [Table 12](#) and [Table 12.1](#) in [Antiretroviral Management for Infants With *In Utero*, Intrapartum, or Breastfeeding Exposure to HIV](#)). If maternal viral load is detectable and breastfeeding continues, some Panel members would recommend monthly virologic testing of the infant as an approach to early detection of HIV infection during ongoing exposure. After cessation of breastfeeding, irrespective of when breastfeeding ends,

virologic testing should be performed at 4 to 6 weeks and 4 to 6 months after cessation of breastfeeding. If the breastfed infant is receiving presumptive HIV therapy or ARV prophylaxis, this virologic testing should be performed at least 2 weeks after discontinuation of infant ARV administration. Consultation with an expert and/or the [National Perinatal HIV Hotline](#) (8884488765) is recommended in these situations and for questions about HIV diagnostic testing for infants with perinatal HIV exposure who are being breastfed. For additional information, see [Preventing HIV Transmission During Infant Feeding](#).

Table 13. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV

Infants With Perinatal HIV Exposure ^a	
Risk Category	Age at HIV NAT ^{b,c} Testing
<p>Infants at High Risk of HIV Acquisition</p> <p>Infants with perinatal HIV exposure to—</p> <ul style="list-style-type: none"> Viremia (HIV RNA ≥ 50 copies/mL) in the 4 weeks prior to delivery Early (acute or recent) HIV during pregnancy or HIV diagnosed in labor or postpartum <p>Note: Viremia can be documented by a laboratory or presumed by other clinical factors (e.g., new diagnosis, ART adherence challenges, stopping ART prior to delivery).</p>	<p>Birth</p> <p>14–21 days</p> <p>1–2 months</p> <p>2–3 months (see note below)</p> <p>4–6 months</p> <p>All infants at high risk of perinatal HIV transmission should have specimens obtained for HIV testing at birth before or immediately after initiating an ARV drug regimen; however, presumptive HIV therapy should not be delayed.</p> <p>Note: Additional virologic testing is recommended 2 to 6 weeks after infant ARV drugs are discontinued (i.e., at age 2 to 3 months if the infant receives 6 weeks of ARV drugs).</p> <p>If an infant's NAT test result is positive, a repeat test should be performed as soon as possible and ART should be initiated.</p>
<p>Infants at Low Risk of HIV Acquisition Who Are Not Being Breastfed</p> <p>Infants with perinatal HIV exposure to—</p> <ul style="list-style-type: none"> Sustained viral suppression (<50 copies/mL) from 20 weeks of gestation through delivery <p>Note: Ideally, sustained viral suppression is documented by HIV RNA testing, including at least two consecutive tests obtained at least 4 weeks apart with HIV RNA <50 copies/mL, but can be based on the clinical judgment of providers.</p>	<p>Birth (see note below)</p> <p>14–21 days</p> <p>1–2 months (see note below)</p> <p>4–6 months</p> <p>Note: A birth test generally should be performed but is not necessary for infants at low risk of HIV acquisition unless there are concerns that the newborn could be lost to follow-up without further testing.</p> <p>Note: For infants at low risk of HIV acquisition, testing may be timed to occur at least 2 weeks after cessation of ZDV prophylaxis.</p>
<p>Infants Not Meeting Criteria for High or Low Risk of HIV Acquisition</p> <ul style="list-style-type: none"> In these clinical scenarios, some infants may receive presumptive HIV therapy and others may receive only ZDV prophylaxis. 	<p>For all infants in this group, a NAT should be obtained at birth and the NAT testing schedule for infants at high risk of HIV acquisition (shown above) should be followed.</p>

	The timing of virologic testing 2 to 6 weeks after ARV drugs are discontinued will vary based on the duration of infant ARV drugs.
See Table 11 and Table 11.1 in Antiretroviral Management of Infants With <i>In Utero</i>, Intrapartum, or Breastfeeding Exposure to HIV for information about presumptive HIV therapy and ZDV prophylaxis, including duration of ARV drugs.	
Infants With Perinatal HIV Exposure at Low Risk of HIV Acquisition Who Are Being Breastfed	
Guidance for Virologic Testing During Breastfeeding	Age at HIV NAT^{b,c} Testing
From Birth to Age 6 Months A NAT test at birth is recommended for infants with perinatal HIV exposure who are at low risk of HIV acquisition and are being breastfed.	Birth 14–21 days 1–2 months (see note below) 4–6 months Note: NAT testing of the infant should be performed at least every 3 months during breastfeeding. An additional virologic test should be performed if the gap between the tests at ages 1 to 2 months and 4 to 6 months is greater than 3 months. In addition to the standard time points after birth, NAT testing also should be performed at 4 to 6 weeks and 4 to 6 months after cessation of breastfeeding, regardless of the age when breastfeeding ends.
If Breastfeeding Continues Beyond 6 Months of Age	NAT testing of the infant should be performed at least every 3 months during breastfeeding and at 4 to 6 weeks and 4 to 6 months after cessation of breastfeeding, regardless of the age when breastfeeding ends.
If Viremia Develops While Breastfeeding (a detectable viral load)	Prompt NAT testing of the infant Additional testing time points are based on the clinical scenario and use of infant ARV prophylaxis or presumptive HIV therapy; see Table 12 in Antiretroviral Management of Infants With <i>In Utero</i>, Intrapartum, or Breastfeeding Exposure to HIV . If there is a detectable maternal viral load and breastfeeding continues, some Panel members would recommend monthly virologic testing of the infant as an approach to early detection of HIV infection during ongoing exposure. Consultation with an expert is recommended to determine the need for infant ARV prophylaxis or presumptive HIV therapy and additional testing time points.
Consultation with an expert and/or the National Perinatal HIV Hotline (888-448-8765) is recommended for questions about HIV diagnostic testing for infants with perinatal HIV exposure who are being breastfed. See Table 12 in Antiretroviral Management of Infants With <i>In Utero</i>, Intrapartum, or Breastfeeding Exposure to HIV for information about extended ARV prophylaxis and presumptive HIV therapy during breastfeeding. See Preventing HIV Transmission During Infant Feeding for additional guidance about breastfeeding.	

^a This table summarizes standard time points for HIV virologic diagnostic testing of infants according to risk of perinatal acquisition.

^b HIV RNA or HIV DNA NATs that directly detect HIV.

^c If maternal HIV-2 infection is suspected or confirmed, infant testing for HIV-2 can follow the same schedule (see [Virologic Assays to Diagnose HIV-2 Infections](#) below).

Key: ART = antiretroviral therapy; ARV = antiretroviral; NAT = nucleic acid test; ZDV = zidovudine

Diagnostic Testing in Children With Postnatal HIV Exposure

Infants and children with potential HIV exposure after birth (e.g., HIV diagnosed during breastfeeding, premasticated feeding, sexual abuse, contaminated blood products, percutaneous exposure) require age-appropriate testing. Infants with perinatal HIV exposure who have these additional exposures after birth require HIV NAT testing for diagnosis. Infants aged <18 months who were not exposed to HIV at delivery and infants aged ≥18 months who have these potential exposures require HIV antigen/antibody testing, unless the time between potential exposure and testing indicates that the patient is in the window for seroconversion, when an HIV NAT is more sensitive. Repeat testing may still be required (see [Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure](#) for additional information).

New HIV Diagnosis While Breastfeeding

Infants may be exposed to HIV through breastfeeding if acute or primary maternal HIV infection occurs or when pre-existing HIV infection was not diagnosed during pregnancy or postpartum.²³ Diagnosis of HIV during breastfeeding should prompt health care professionals to counsel to discontinue breastfeeding immediately to reduce the risk of postnatal transmission to the infant. In these situations, infant virologic diagnostic testing using an HIV NAT is recommended immediately and 14 to 21 days, 4 to 6 weeks, and 4 to 6 months after the infant's last exposure to breast milk (i.e., cessation of breastfeeding). A virologic test also should be performed at least 2 weeks after cessation of presumptive HIV therapy if provided (see [ARV Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV](#)). Duplicate tests are not needed if some of these time points overlap with standard post-natal testing. For additional information, consult the [National Perinatal HIV Hotline](#) (1-888-448-8765).

Premastication

Receipt of solid food that has been premasticated or prewarmed in the mouth by a caregiver with HIV is associated with risk of HIV transmission.²⁴⁻³⁰ If this occurs in children with perinatal HIV exposure aged <18 months with prior negative virologic tests, it will be necessary for such children to undergo virologic diagnostic testing because they may have residual HIV antibodies from the antepartum period (see Special Situations below).

Additional Routes of HIV Transmission

Additional routes of HIV transmission in children include sexual abuse, receipt of contaminated blood products, and needlestick with contaminated needles. It may be difficult to obtain a history of HIV exposure. Therefore, age-appropriate HIV testing is recommended for infants and children with signs and/or symptoms of HIV infection, even in the absence of documented or suspected perinatal or non-perinatal HIV exposure. Acquisition of HIV in older children is possible through accidental needlestick injuries, sexual transmission, or injection drug use. Medical procedures performed in settings with inadequate infection control practices may pose a potential risk; although tattooing or

body piercing present a potential risk of HIV transmission, no reported cases of HIV transmission from these activities have been documented.³¹

Diagnostic Testing

Diagnosis of HIV-1 infection in infants and children with non-perinatal HIV exposure only or in children with perinatal HIV exposure who are aged ≥ 18 months relies primarily on HIV antibody and antigen/antibody tests.^{1, 32} U.S. Food and Drug Administration (FDA)–approved diagnostic tests include the following:

- Antigen/antibody combination immunoassays, which detect HIV-1/2 antibodies and HIV-1 p24 antigen. These tests are recommended for initial testing to screen for established infection with HIV-1 or HIV-2 and for acute HIV-1 infection. However, p24 antigen from HIV-1 non-B strains, HIV-1 non-M strains, and HIV-2 strains may not be detected.³³ Recent data suggest that the use of immunoassays and rapid diagnostic test combination algorithms that have limited HIV antigen breadth may not be adequate for diagnosis of HIV infection in children following early treatment with ART.³⁴
- HIV-1/HIV-2 antibody differentiation immunoassay, which differentiates HIV-1 antibodies from HIV-2 antibodies. This immunoassay is recommended for supplemental testing.
- HIV-1 NAT. A NAT always is indicated as an additional test to diagnose acute HIV infection.

For information on diagnosis of HIV-2 infection, see [Virologic Assays to Diagnose HIV-2 Infections](#) below.

Special Situations

Late Seroreversion (Aged ≥ 18 Months)

Non-breastfed children with perinatal HIV exposure, no other HIV transmission risk factor, and no clinical or virologic laboratory evidence of HIV infection may have residual HIV antibodies from the antepartum period up to age 24 months. These children are called late seroreverters.³⁵⁻³⁸ In one study, 14% of children with HIV exposure who did not have HIV infection seroreverted after age 18 months.³⁸ More recent data from Thailand associated late seroreversion with the antenatal use of protease inhibitors in pregnant women with HIV. In this study, late seroreversion also was associated with the use of fourth-generation combination antigen/antibody immunoassays.³⁹ These children may have had positive immunoassay results, but supplemental antibody test results indicated indeterminate HIV status. In such cases, repeat antibody testing at a later date confirmed seroreversion. Due to the possibility of residual maternal HIV antibodies, virologic testing is necessary to definitively exclude or confirm HIV infection in children with perinatal HIV exposure who have a positive HIV antibody (or antigen/antibody) test at age ≥ 18 months. Virologic testing will distinguish late-seroreverting children who do not have HIV but have residual antibodies from children who have antibodies due to underlying HIV infection. Age-appropriate HIV testing also is recommended for infants and children with signs and/or symptoms of HIV, even in the absence of documented or suspected HIV exposure.

Postnatal HIV Infection in Children With Perinatal HIV Exposure and Prior Negative Virologic Test Results for Whom There Are Additional HIV Transmission Risks

In contrast to late seroreverters, in rare situations, postnatal HIV infections have been reported in children with HIV exposure who had prior negative HIV virologic test results. This occurs in children who acquire HIV through an additional risk factor after completion of testing.

Suspicion of HIV-2 or Non-Subtype B HIV-1 Infections With False-Negative Virologic Test Results

Children with non-subtype B HIV-1 and children with HIV-2 may have false-negative virologic tests but persistent positive immunoassay results.⁴⁰⁻⁴² The diagnostic approach in these situations is discussed below in Virologic Assays to Diagnose Group M Non-Subtype B and Group O HIV-1 Infections and in Virologic Assays to Diagnose HIV-2 Infections.

Virologic Assays to Diagnose HIV in Infants Younger Than 18 Months With Perinatal HIV-1 Exposure

HIV RNA Assays

HIV quantitative RNA assays detect extracellular viral RNA in plasma. Their specificity has been shown to be 100% at birth and age 1 month, 3 months, and 6 months and is comparable to the specificity of HIV DNA PCR.¹⁹ Testing at birth will detect HIV RNA in infants who acquire HIV *in utero* and not in those who acquire HIV from exposure during delivery or immediately before delivery (i.e., during the intrapartum period). Studies have shown that HIV RNA assays identify 25% to 58% of infants with HIV infection from birth through the first week of life, 89% at age 1 month, and 90% to 100% by age 2 months to 3 months. These results are similar to the results of HIV DNA PCR for early diagnosis of HIV.³

The sensitivity of HIV RNA assays is affected by maternal antenatal ART or ARV drugs administered to the infant as prophylaxis or presumptive therapy.⁴³ In one study, the sensitivity of HIV RNA assays was not associated with the type of maternal ART or infant ARV prophylaxis, but HIV RNA levels at 1 month were significantly lower in infants with HIV who were receiving multidrug prophylaxis. In contrast, the median HIV RNA levels were high by age 3 months in both groups after stopping prophylaxis.¹⁹ Between 2010 and 2016, a significant decline in baseline viremia was noted in South Africa's Early Infant Diagnosis program, with loss of detectability documented among some infants with HIV. This decline may have reflected the administration of various prophylactic ARV regimens during those years.⁴⁴ Further studies are necessary to evaluate the sensitivity of HIV RNA assays during receipt of multidrug ARV prophylaxis or presumptive HIV therapy in infants when maternal antenatal ART was received.

An HIV quantitative RNA assay can be used as a confirmatory test for infants who have an initial positive HIV DNA PCR test result. In addition to providing virologic confirmation of infection status, an HIV RNA measurement assesses baseline viral load. An HIV genotype can be performed on the same sample to guide initial ARV treatment in an infant with HIV.

An HIV qualitative RNA assay is an alternative diagnostic test that can be used for infant testing.^{16, 45-49}

HIV DNA PCR and Related Assays

HIV DNA PCR is a sensitive technique that is used to detect intracellular HIV viral DNA in peripheral blood mononuclear cells. The specificity of the HIV DNA PCR is 99.8% at birth and 100% at age 1 month, 3 months, and 6 months. Studies have shown that HIV DNA PCR assays identify 20% to 55% of infants with HIV infection from birth through the first week of life, with the same caveat as for RNA testing—testing at birth detects only *in utero* HIV infection and not infection in those infants who acquire HIV during the intrapartum period. This percentage increases to >90% by age 2 weeks to 4 weeks and to 100% at age 3 months and 6 months.^{3, 16}

Two studies provided data on diagnostic testing at different time points in infants with confirmed HIV infection, including those who had negative test results at birth. One study noted that among 47 infants with HIV infection who had negative DNA PCR test results at birth, 68% were identified during the period of neonatal ARV prophylaxis at 4 to 6 weeks; by 3 months, all 47 infants were identified.¹⁸ Another study from Cape Town evaluated the sensitivity of HIV DNA assays within 8 days of life during and after initiating ART in infants with HIV. The infants had been exposed to ART *in utero* and ARV drugs for prophylaxis and treatment. In seven infants who achieved virologic suppression (defined as a continuous downward trend in plasma HIV RNA, with <100 copies/mL after 6 months), total HIV DNA continued to decay over 12 months. The authors noted that one infant had undetectable HIV DNA after 6 days on treatment, another had undetectable HIV DNA after 3 months, and a third had undetectable HIV DNA after 4 months, suggesting that rapid decline of HIV-1 RNA and DNA may complicate definitive diagnosis.⁵⁰ A data set of 38,043 infants from the Western Cape province of South Africa who were tested at a median age of 45 days showed that infants who received the World Health Organization Option B+ ARV regimen had fewer indeterminate DNA PCR results than infants who were receiving older ARV regimens.⁵¹ Another group of South African investigators reported similar findings in a study of a cohort of 5,743 neonates from Johannesburg who were exposed to HIV.⁵²

The AMPLICOR[®] HIV-1 DNA test has been used widely for diagnosis of HIV in infants perinatally exposed to HIV-1 infection since it was introduced in 1992. However, it is no longer commercially available in the United States. The sensitivity and specificity of noncommercial HIV-1 DNA tests that use individual laboratory reagents may differ from the sensitivity and specificity of an FDA-approved commercial test. These considerations underscore the importance of testing with HIV NATs at 4 months—well after neonatal ARV prophylaxis or presumptive HIV therapy has stopped.

Other Issues

Virologic Assays to Diagnose Group M Non-Subtype B and Group O HIV-1 Infections

Although HIV-1 Group M subtype B is the predominant viral subtype found in the United States, multiple subtypes and recombinant forms also are found in the United States.⁵³ Data from the CDC National HIV Surveillance System (NHSS) showed that the number of non-U.S. born children with HIV **living in the United States** has exceeded the number of U.S.-born children with HIV since 2011, with 65.5% of non-U.S. born children with HIV born in sub-Saharan Africa and 14.3% in Eastern Europe.⁵⁴ In an evaluation of infants who received a perinatal HIV infection diagnosis in New York

State in 2001 and 2002, 16.7% of infants had acquired a non-subtype B strain of HIV compared with 4.4% of infants born in 1998 and 1999.⁵⁵ Among a group of 40 children who visited a pediatric HIV clinic in Rhode Island between 1991 and 2012, 14 (35%) acquired HIV with non-B HIV-1 subtypes. All 14 children were either born outside the United States or their parents were of foreign origin.⁵⁶ In an analysis of 1,277 unique sequences collected in Rhode Island from 2004 to 2011, 8.3% were non-B subtypes (including recombinant forms). Twenty-two percent of participants with non-B subtypes formed transmission clusters, including individuals with perinatally acquired infection.⁵⁷ In an analysis of 3,895 HIV-1 sequences that were collected between July 2011 and June 2012 in the United States, 5.3% were determined to be non-B subtypes (including recombinant forms).

Evolving immigration patterns may be contributing to local and regional increases in HIV-1 subtype diversity. Non-subtype B viruses predominate in other parts of the world, such as subtype C in regions of Africa and India and subtype CRF01 in much of Southeast Asia. Group O HIV strains are seen in West-Central Africa.⁵⁸ Non-subtype B and Group O strains may be seen in countries with links to these geographical regions.⁵⁹⁻⁶³ The geographical distribution of HIV groups is available at the [HIV Sequence Database](#).

Current HIV RNA PCR assays and the qualitative diagnostic RNA assays are better at detecting non-subtype B HIV infection and the less-common Group O strains than older RNA assays^{5-10, 49} (see [Clinical and Laboratory Monitoring of Pediatric HIV Infection](#)). The increased sensitivity is due to amplification of more than one highly conserved region of the HIV genome. HIV DNA assays, though generally less sensitive, may be more sensitive in detecting HIV infection when the infant is receiving ART because identification is based on detection of cell-associated DNA in whole blood or dried blood spots and does not rely on active viral replication.^{16, 64}

A qualitative RNA assay, a quantitative RNA assay, or a total DNA/RNA (total nucleic acid) test should be used for infant testing in addition to a DNA PCR assay when evaluating an infant exposed to HIV infection linked to an area that is endemic for non-subtype B HIV or Group O strains, such as Africa or Southeast Asia. **These additional tests are also indicated** when initial testing is negative using an HIV DNA PCR test and non-subtype B or Group O perinatal exposure is suspected. Two negative HIV antibody test results obtained at age ≥ 6 months provide further evidence to rule out HIV infection definitively. Clinicians should consult with an expert in pediatric HIV infection; state or local public health departments or CDC may be able to assist in obtaining referrals for diagnostic HIV testing.

Chimeric Antigen Receptor T-Cell and Lentiviral-Based Gene Therapy May Give Rise to False-Positive HIV NAT Results

Chimeric antigen receptor (CAR) T-cell immunotherapy is a major advancement in cancer therapeutics, including for pediatric B-cell acute lymphoblastic leukemia. Reprogramming of T cells is achieved by using gammaretroviral or lentiviral vectors. Recent reports indicate that these vectors may interfere with long terminal repeat genomes in HIV NAT results and, thus, produce false-positive results. As CAR T-cell therapy becomes more widely available for multiple indications, it will be important for clinicians to recognize that routine HIV-1 NAT results may give rise to false results. In addition, lentiviral vector-based gene therapy as treatment for severe combined immunodeficiency can give rise to false-positive HIV NAT results. Laboratories should, therefore, have appropriate alternate HIV-1 NAT resulting platforms made available for this emerging patient population.⁶⁵⁻⁶⁹

Virologic Assays to Diagnose HIV-2 Infections

HIV-2 infection is endemic in Angola; Mozambique; West African countries, including Benin, Burkina Faso, Cape Verde, the Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Mauritania, Niger, Nigeria, Sao Tome, Senegal, Sierra Leone, and Togo; and parts of India.⁷⁰⁻⁷² HIV-2 infection also is well documented in France and Portugal, which have large numbers of immigrants from these regions.^{73, 74} HIV-1 and HIV-2 coinfection may occur, but this rarely is described outside areas where HIV-2 is endemic. HIV-2 is rare in the United States. Although accurately diagnosing HIV-2 can be difficult, it is clinically important because HIV-2 strains are resistant to several ARV drugs that were developed to suppress HIV-1.⁷⁵⁻⁷⁷ (See [HIV-2 Infection and Pregnancy](#).)

HIV-2 should be suspected if HIV infection is linked to an area that is endemic for HIV-2 infection or if HIV test results are suggestive of HIV-2 infection (i.e., positive initial HIV 1/2 immunoassay test result and HIV-1 RNA viral loads that are at or below the limit of detection in the absence of treatment). The current recommendation is to use an HIV-1/HIV-2 antibody differentiation immunoassay for supplemental testing.¹

Between 2010 and 2017, an increase in the number of HIV-1/HIV-2 differentiation test results was reported to the CDC's NHSS. More than 99.9% of all HIV infections identified in the United States were categorized as HIV-1, and the number of HIV-2 diagnoses (mono-infection or dual-infection) remained extremely low (<0.03% of all HIV infections).⁷⁸

Infant testing with HIV-2–specific DNA PCR tests should be performed at time points similar to those used for HIV-1 testing when evaluating an infant exposed to known or suspected HIV-2 infection. HIV-2 DNA PCR testing can be arranged by the HIV surveillance program of the state or local health department through their public health laboratory, or the CDC, because this assay is not commercially available.^{79, 80} Clinicians should consult with an expert in pediatric HIV infection when caring for infants with suspected or known exposure to HIV-2.^{70, 81}

The diagnosis of HIV-2 in children with only non-perinatal exposure or in children with perinatal exposure aged ≥ 18 months should also follow the Centers for Disease Control and Prevention and Association of Public Health Laboratories 2014 [laboratory testing guidelines](#), which recommend using an HIV-1/HIV-2 antibody differentiation immunoassay that distinguishes between HIV-1 and HIV-2 antibodies for supplemental testing. All HIV-2 cases should be reported to the HIV surveillance program of the state or local health department; additional HIV-2 DNA PCR testing can be arranged by a local public health laboratory or by CDC if an HIV-1/HIV-2 antibody differentiation immunoassay is inconclusive. HIV-2 DNA PCR testing may be necessary for definitive diagnosis, although this assay is not commercially available.^{79, 80}

References

1. Branson BM, Owen, MS, Weslowski, LG. Laboratory testing for the diagnosis of HIV infection: updated recommendations. 2014. Available at: <https://dx.doi.org/10.15620/cdc.23447>.
2. Donovan M, Palumbo P. Diagnosis of HIV: challenges and strategies for HIV prevention and detection among pregnant women and their infants. *Clin Perinatol*. 2010;37(4):751-63, viii. Available at: <https://pubmed.ncbi.nlm.nih.gov/21078448>.
3. Chadwick EG, Ezeanolue EE, Committee on Pediatric AIDS. Evaluation and management of the infant exposed to HIV in the United States. *Pediatrics*. 2020;146(5). Available at: <https://pubmed.ncbi.nlm.nih.gov/33077537>.
4. Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. *Lancet Infect Dis*. 2019;19(2):143-155. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30509777>.
5. Church D, Gregson D, Lloyd T, et al. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. *J Clin Microbiol*. 2011;49(1):118-24. Available at: <https://pubmed.ncbi.nlm.nih.gov/21084515>.
6. Cobb BR, Vaks JE, Do T, et al. Evolution in the sensitivity of quantitative HIV-1 viral load tests. *J Clin Virol*. 2011;52 Suppl 1S77-82. Available at: <https://pubmed.ncbi.nlm.nih.gov/22036041>.
7. Katsoulidou A, Rokka C, Issaris C, et al. Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece. *Virol J*. 2011;810. Available at: <https://pubmed.ncbi.nlm.nih.gov/21219667>.
8. Gueudin M, Leoz M, Lemee V, et al. A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection. *J Clin Microbiol*. 2012;50(3):831-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/22170927>.
9. Xu S, Song A, Nie J, et al. Comparison between the automated Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 assay and its version 1 and Nuclisens HIV-1 EasyQ version 2.0 assays when measuring diverse HIV-1 genotypes in China. *J Clin Virol*. 2012;53(1):33-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/22051503>.
10. Muenchhoff M, Madurai S, Hempenstall AJ, et al. Evaluation of the NucliSens EasyQ v2.0 assay in comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in quantification of C-clade HIV-1 in plasma. *PLoS One*. 2014;9(8):e103983. Available at: <https://pubmed.ncbi.nlm.nih.gov/25157919>.
11. Tamhane M, Gautney B, Shiu C, et al. Analysis of the optimal cut-point for HIV-p24 antigen testing to diagnose HIV infection in HIV-exposed children from resource-

- constrained settings. *J Clin Virol*. 2011;50(4):338-41. Available at: <https://pubmed.ncbi.nlm.nih.gov/21330193>.
12. Wessman MJ, Theilgaard Z, Katzenstein TL. Determination of HIV status of infants born to HIV-infected mothers: a review of the diagnostic methods with special focus on the applicability of p24 antigen testing in developing countries. *Scand J Infect Dis*. 2012;44(3):209-15. Available at: <https://pubmed.ncbi.nlm.nih.gov/22074445>.
 13. Bhowan K, Sherman GG. Performance of the first fourth-generation rapid human immunodeficiency virus test in children. *Pediatr Infect Dis J*. 2013;32(5):486-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/23190776>.
 14. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. 2019. Available at: <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/guidelines-pediatric-oi.pdf>
 15. Jourdain G, Mary JY, Coeur SL, et al. Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. *J Infect Dis*. 2007;196(11):1629-36. Available at: <https://pubmed.ncbi.nlm.nih.gov/18008246>.
 16. Lilian RR, Kalk E, Bhowan K, et al. Early diagnosis of in utero and intrapartum HIV infection in infants prior to 6 weeks of age. *J Clin Microbiol*. 2012;50(7):2373-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/22518871>.
 17. Lilian RR, Kalk E, Technau KG, et al. Birth diagnosis of HIV infection on infants to reduce infant mortality and monitor for elimination of mother-to-child transmission. *Pediatr Infect Dis J*. 2013;32(10):1080-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/23574775>.
 18. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *N Engl J Med*. 2012;366(25):2368-79. Available at: <https://pubmed.ncbi.nlm.nih.gov/22716975>.
 19. Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. *J Pediatr*. 2012;160(1):60-6 e1. Available at: <https://pubmed.ncbi.nlm.nih.gov/21868029>.
 20. Kuhn L, Schramm DB, Shiao S, et al. Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. *AIDS*. 2015;29(9):1053-60. Available at: <https://pubmed.ncbi.nlm.nih.gov/25870988>.
 21. Payne H, Mkhize N, Ot wombe K, et al. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the children with HIV early antiretroviral therapy (CHER) trial: a retrospective analysis. *Lancet Infect Dis*. 2015;15(7):803-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/26043884>.

22. Levison J, McKinney J, Duque A, et al. Breastfeeding among people with HIV in North America: a multisite study. *Clin Infect Dis*. 2023. Available at: <https://pubmed.ncbi.nlm.nih.gov/37078712>.
23. Swain CA, Kaufman S, Miranda W, et al. Postpartum mother-to-child transmission of HIV in a breastfeeding infant. *Pediatrics*. 2022;149(2). Available at: <https://pubmed.ncbi.nlm.nih.gov/35043205>.
24. Centers for Disease Control and Prevention. Premastication of food by caregivers of HIV-exposed children--nine U.S. sites, 2009–2010. *MMWR Morb Mortal Wkly Rep*. 2011;60(9):273-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/21389930>.
25. Gaur AH, Freimanis-Hance L, Dominguez K, et al. Knowledge and practice of prechewing/prewarming food by HIV-infected women. *Pediatrics*. 2011;127(5):e1206-11. Available at: <https://pubmed.ncbi.nlm.nih.gov/21482608>.
26. Hafeez S, Salami O, Alvarado M, et al. Infant feeding practice of premastication: an anonymous survey among human immunodeficiency virus-infected mothers. *Arch Pediatr Adolesc Med*. 2011;165(1):92-3. Available at: <https://pubmed.ncbi.nlm.nih.gov/21199989>.
27. Maritz ER, Kidd M and Cotton MF Premasticating food for weaning African infants: a possible vehicle for transmission of HIV. *Pediatrics*. 2011;128(3):e579-90. Available at: <https://pubmed.ncbi.nlm.nih.gov/21873699>.
28. Ivy W, 3rd, Dominguez KL, Rakhmanina NY, et al. Premastication as a route of pediatric HIV transmission: case-control and cross-sectional investigations. *J Acquir Immune Defic Syndr*. 2012;59(2):207-12. Available at: <https://pubmed.ncbi.nlm.nih.gov/22027873>.
29. Gaur AH, Cohen RA, Read JS, et al. Prechewing and prewarming food for HIV-exposed children: a prospective cohort experience from Latin America. *AIDS Patient Care STDS*. 2013;27(3):142-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/23477456>.
30. Nash SH, Rutledge M, Frenkel LM, et al. HIV transmission through premastication. *Pediatrics*. 2022;150(4). Available at: <https://pubmed.ncbi.nlm.nih.gov/36052601>.
31. Centers for Disease Control and Prevention. HIV transmission. 2018.
32. Alexander TS. Human immunodeficiency virus diagnostic testing: 30 years of evolution. *Clin Vaccine Immunol*. 2016;23(4):249-53. Available at: <https://pubmed.ncbi.nlm.nih.gov/26936099>.
33. Ly TD, Plantier JC, Leballais L, et al. The variable sensitivity of HIV Ag/Ab combination assays in the detection of p24Ag according to genotype could compromise the diagnosis of early HIV infection. *J Clin Virol*. 2012;55(2):121-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/22795598>.

34. Puthanakit T, Ananworanich J, Akapirat S, et al. Pattern and frequency of seroreactivity to routinely used serologic tests in early-treated infants with HIV. *J Acquir Immune Defic Syndr*. 2020;83(3):260-266. Available at: <https://pubmed.ncbi.nlm.nih.gov/31917751>.
35. Sohn AH, Thanh TC, Thinh le Q, et al. Failure of human immunodeficiency virus enzyme immunoassay to rule out infection among polymerase chain reaction-negative Vietnamese infants at 12 months of age. *Pediatr Infect Dis J*. 2009;28(4):273-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/19289981>.
36. Gulia J, Kumwenda N, Li Q, et al. HIV seroreversion time in HIV-1-uninfected children born to HIV-1-infected mothers in Malawi. *J Acquir Immune Defic Syndr*. 2007;46(3):332-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/17786126>.
37. Alcantara KC, Pereira GA, Albuquerque M, et al. Seroreversion in children born to HIV-positive and AIDS mothers from Central West Brazil. *Trans R Soc Trop Med Hyg*. 2009;103(6):620-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/19339030>.
38. Gutierrez M, Ludwig DA, Khan SS, et al. Has highly active antiretroviral therapy increased the time to seroreversion in HIV exposed but uninfected children? *Clin Infect Dis*. 2012;55(9):1255-61. Available at: <https://pubmed.ncbi.nlm.nih.gov/22851494>.
39. Chatpornvorarux S, Maleesatharn A, Rungmaitree S, et al. Delayed seroreversion in HIV-exposed uninfected infants. *Pediatr Infect Dis J*. 2019;38(1):65-69. Available at: <https://pubmed.ncbi.nlm.nih.gov/30239474>.
40. Kline NE, Schwarzwald H, Kline MW. False negative DNA polymerase chain reaction in an infant with subtype C human immunodeficiency virus 1 infection. *Pediatr Infect Dis J*. 2002;21(9):885-6. Available at: <https://pubmed.ncbi.nlm.nih.gov/12380591>.
41. Zaman MM, Recco RA, Haag R. Infection with non-B subtype HIV type 1 complicates management of established infection in adult patients and diagnosis of infection in newborn infants. *Clin Infect Dis*. 2002;34(3):417-8. Available at: <https://pubmed.ncbi.nlm.nih.gov/11774090>.
42. Obaro SK, Losikoff P, Harwell J, et al. Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G. *Pediatr Infect Dis J*. 2005;24(2):183-4. Available at: <https://pubmed.ncbi.nlm.nih.gov/15702052>.
43. Saitoh A, Hsia K, Fenton T, et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. *J Infect Dis*. 2002;185(10):1409-16. Available at: <https://pubmed.ncbi.nlm.nih.gov/11992275>.
44. Mazanderani AH, Moyo F, Kufa T, et al. Brief report: declining baseline viremia and escalating discordant HIV-1 confirmatory results within South Africa's Early Infant Diagnosis program, 2010–2016. *J Acquir Immune Defic Syndr*. 2018;77(2):212-216. Available at: <https://pubmed.ncbi.nlm.nih.gov/29084045>.

45. Food and Drug Administration. APTIMA HIV-1 RNA qualitative assay. 2019. Available at: <https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm149922.htm>.
46. Pierce VM, Neide B, Hodinka RL. Evaluation of the Gen-Probe Aptima HIV-1 RNA qualitative assay as an alternative to Western blot analysis for confirmation of HIV infection. *J Clin Microbiol.* 2011;49(4):1642-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/21346052>.
47. Fiscus SA, McMillion T, Nelson JA, et al. Validation of the Gen-Probe Aptima qualitative HIV-1 RNA assay for diagnosis of human immunodeficiency virus infection in infants. *J Clin Microbiol.* 2013;51(12):4137-40. Available at: <https://pubmed.ncbi.nlm.nih.gov/24088864>.
48. Nelson JA, Hawkins JT, Schanz M, et al. Comparison of the Gen-Probe Aptima HIV-1 and Abbott HIV-1 qualitative assays with the Roche Amplicor HIV-1 DNA assay for early infant diagnosis using dried blood spots. *J Clin Virol.* 2014;60(4):418-21. Available at: <https://pubmed.ncbi.nlm.nih.gov/24929752>.
49. Hans L, Allmen NV, Edelmann A, et al. Early diagnosis of HIV-1 and HIV-2 using COBAS HIV-1/HIV-2 qualitative test: a novel qualitative nucleic acid amplification test for plasma, serum, and dried blood spot specimens. *J Acquir Immune Defic Syndr.* 2021;87(5):1187-1195. Available at: <https://pubmed.ncbi.nlm.nih.gov/33883470>.
50. Veldsman KA, Maritz J, Isaacs S, et al. Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge. *AIDS.* 2018;32(5):629-634. Available at: <https://pubmed.ncbi.nlm.nih.gov/29334551>.
51. Maritz J, Maharaj JN, Cotton MF, et al. Interpretation of indeterminate HIV-1 PCR results are influenced by changing vertical transmission prevention regimens. *J Clin Virol.* 2017;9586-89. Available at: <https://pubmed.ncbi.nlm.nih.gov/28898704>.
52. Technau KG, Mazanderani AH, Kuhn L, et al. Prevalence and outcomes of HIV-1 diagnostic challenges during universal birth testing - an urban South African observational cohort. *J Int AIDS Soc.* 2017;20(Suppl 6):21761. Available at: <https://pubmed.ncbi.nlm.nih.gov/28872276>.
53. Pyne MT, Hackett J, Jr., Holzmayer V, et al. Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States. *J Clin Microbiol.* 2013;51(8):2662-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/23761148>.
54. Nesheim SR, Linley L, Gray KM, et al. Country of birth of children with diagnosed HIV infection in the United States, 2008–2014. *J Acquir Immune Defic Syndr.* 2018;77(1):23-30. Available at: <https://pubmed.ncbi.nlm.nih.gov/29040167>.

55. Karchava M, Pulver W, Smith L, et al. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. *J Acquir Immune Defic Syndr*. 2006;42(5):614-9. Available at: <https://pubmed.ncbi.nlm.nih.gov/16868498>.
56. Rogo T, DeLong AK, Chan P, et al. Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island. *Clin Infect Dis*. 2015;60(9):1426-35. Available at: <https://pubmed.ncbi.nlm.nih.gov/25637585>.
57. Chan PA, Reitsma MB, DeLong A, et al. Phylogenetic and geospatial evaluation of HIV-1 subtype diversity at the largest HIV center in Rhode Island. *Infect Genet Evol*. 2014;28358-66. Available at: <https://pubmed.ncbi.nlm.nih.gov/24721515>.
58. Bush S, Tebit DM. HIV-1 group O origin, evolution, pathogenesis, and treatment: unraveling the complexity of an outlier 25 years later. *AIDS Rev*. 2015;17(3):147-58. Available at: <https://pubmed.ncbi.nlm.nih.gov/26450803>.
59. Auwanit W, Isarangkura-Na-Ayuthaya P, Kasornpikul D, et al. Detection of drug resistance-associated and background mutations in human immunodeficiency virus type 1 CRF01_AE protease and reverse transcriptase derived from drug treatment-naive patients residing in central Thailand. *AIDS Res Hum Retroviruses*. 2009;25(6):625-31. Available at: <https://pubmed.ncbi.nlm.nih.gov/19500016>.
60. Deshpande A, Jauvin V, Pinson P, et al. Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. *AIDS Res Hum Retroviruses*. 2009;25(6):633-5. Available at: <https://pubmed.ncbi.nlm.nih.gov/19534630>.
61. Chaix ML, Seng R, Frange P, et al. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. *Clin Infect Dis*. 2013;56(6):880-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/23223603>.
62. Hemelaar J, Gouws E, Ghys PD, et al. Global trends in molecular epidemiology of HIV-1 during 2000–2007. *AIDS*. 2011;25(5):679-89. Available at: <https://pubmed.ncbi.nlm.nih.gov/21297424>.
63. Dauwe K, Mortier V, Schauvliege M, et al. Characteristics and spread to the native population of HIV-1 non-B subtypes in two European countries with high migration rate. *BMC Infect Dis*. 2015;15524. Available at: <https://pubmed.ncbi.nlm.nih.gov/26572861>.
64. Mitchell C, Dross S, Beck IA, et al. Low concentrations of HIV-1 DNA at birth delays diagnosis, complicating identification of infants for antiretroviral therapy to potentially prevent the establishment of viral reservoirs. *Clin Infect Dis*. 2014;58(8):1190-3. Available at: <https://pubmed.ncbi.nlm.nih.gov/24501389>.
65. Hauser JR, Hong H, Babady NE, et al. False-positive results for human immunodeficiency virus type 1 nucleic acid amplification testing in chimeric antigen

- receptor T cell therapy. *J Clin Microbiol*. 2019;58(1):e01420-19. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31694968>.
66. Laetsch TW, Maude SL, Milone MC, et al. False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. *Blood*. 2018;131(23):2596-2598. Available at: <https://pubmed.ncbi.nlm.nih.gov/29669777>.
 67. Ariza-Heredia EJ, Granwehr BP, Viola GM, et al. False-positive HIV nucleic acid amplification testing during CAR T-cell therapy. *Diagn Microbiol Infect Dis*. 2017;88(4):305-307. Available at: <https://pubmed.ncbi.nlm.nih.gov/28610774>.
 68. Milone MC, O'Doherty U. Clinical use of lentiviral vectors. *Leukemia*. 2018;32(7):1529-1541. Available at: <https://pubmed.ncbi.nlm.nih.gov/29654266>.
 69. De Ravin SS, Gray JT, Throm RE, et al. False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector. *Mol Ther*. 2014;22(2):244-245. Available at: <https://pubmed.ncbi.nlm.nih.gov/24487563>.
 70. Torian LV, Eavey JJ, Punsalang AP, et al. HIV type 2 in New York City, 2000–2008. *Clin Infect Dis*. 2010;51(11):1334-42. Available at: <https://pubmed.ncbi.nlm.nih.gov/21039219>.
 71. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. *Clin Infect Dis*. 2011;52(6):780-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/21367732>.
 72. Prince PD, Matser A, van Tienen C, et al. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. *AIDS*. 2014;28(4):549-58. Available at: <https://pubmed.ncbi.nlm.nih.gov/23921613>.
 73. Barin F, Cazein F, Lot F, et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003–2006. *AIDS*. 2007;21(17):2351-3. Available at: <https://pubmed.ncbi.nlm.nih.gov/18090288>.
 74. Thiebaut R, Matheron S, Taieb A, et al. Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. *AIDS*. 2011;25(6):865-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/21358376>.
 75. Menendez-Arias L, Alvarez M. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. *Antiviral Res*. 2014;10270-86. Available at: <https://pubmed.ncbi.nlm.nih.gov/24345729>.
 76. Tchounga BK, Inwoley A, Coffie PA, et al. Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients among the HIV-2 cohort of the West African database to evaluate AIDS collaboration. *J Int AIDS Soc*. 2014;1719064. Available at: <https://pubmed.ncbi.nlm.nih.gov/25128907>.

77. Balestre E, Ekouevi DK, Tchounga B, et al. Immunologic response in treatment-naive HIV-2-infected patients: the IeDEA West Africa cohort. *J Int AIDS Soc*. 2016;19(1):20044. Available at: <https://pubmed.ncbi.nlm.nih.gov/26861115>.
78. Peruski AH, Wesolowski LG, Delaney KP, et al. Trends in HIV-2 diagnoses and use of the HIV-1/HIV-2 differentiation test - United States, 2010–2017. *MMWR Morb Mortal Wkly Rep*. 2020;69(3):63-66. Available at: <https://pubmed.ncbi.nlm.nih.gov/31971928>.
79. Shanmugam V, Switzer WM, Nkengasong JN, et al. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. *J Acquir Immune Defic Syndr*. 2000;24(3):257-63. Available at: <https://pubmed.ncbi.nlm.nih.gov/10969350>.
80. Damond F, Benard A, Balotta C, et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. *J Clin Microbiol*. 2011;49(10):3491-7. Available at: <https://pubmed.ncbi.nlm.nih.gov/21813718>.
81. Burgard M, Jasseron C, Matheron S, et al. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. *Clin Infect Dis*. 2010;51(7):833-43. Available at: <https://pubmed.ncbi.nlm.nih.gov/20804413>.